en.energymedresearch.com
drugs

TOKEN ® Calcipotriol + Betamethasone

TOKEN ® is a drug based on Calcipotriol + Betamethasone

THERAPEUTIC GROUP: Antipsoriatics for topical use

IndicationsAction mechanismStudies and clinical effectiveness Usage and dosage instructionsWarnings Pregnancy and lactationInteractionsContraindicationsUndesirable effects

Indications TOKEN ® Calcipotriol + Betamethasone

TOKEN ® is used in the treatment of adult plaque psoriasis.

Mechanism of action TOKEN ® Calcipotriol + Betamethasone

TOKEN ® is a drug based on Calcipotriol and Betamethasone, active ingredients with complementary therapeutic activities, and therefore able to treat psoriatic disease on several fronts.

More precisely, Calcipotriol, as a synthetic analogue of Vitamin D3, with which it shares the different biological mechanisms, is able to easily permeate the plasma membrane of keratinocytes, interacting with nuclear receptors involved in the regulation of gene expression.

This interaction induces a series of modifications affecting gene expression, such as to reduce the proliferative effectiveness of the keratinocyte, probably also through the induction of the apoptotic process, and to restore the differentiation phenomenon, important in the stabilization of the histological features of the lesion.

Betamethasone, on the other hand, as a synthetic corticosteroid, is able to inhibit the expression of inflammatory cytokines, while also limiting the recruitment of inflammatory cells, and thus controlling the phlogistic evolution of the pathology and some of the associated symptoms.

The whole is supported by the advantageous pharmacokinetic properties that significantly limit the systemic absorption of the two active ingredients.

Studies carried out and clinical efficacy

CALCIPOTRIOLO / BETAMETASONE: Review

Am J Clin Dermatol. 2004; 5 (6): 463-78.

Very interesting review that evaluates the short and long term effects of therapy with Calcipotriol / Betamethasone of psoriasis vulgaris, emphasizing the excellent efficacy and safety of the same, despite the presence of corticosteroids.

HISTOLOGY OF TREATMENT WITH CALCIPOTRIOLO / BETAMETASONE

J Dermatolog Treat. 2010 Jan; 21 (1): 13-22. doi: 10.3109 / 09546630903214175.

Histology study that demonstrates the greater efficacy of the Calcipotriol / Betamethasone association in the treatment of plaque psoriasis, observing also at the microscopic level a clear improvement of the lesions and a reduction of the inflammatory infiltrate.

CALCIPOTRIOLO AND BETAMETASONE IN THE TREATMENT OF VITILIGINE

J Drugs Dermatol. 2012 Oct; 11 (10): e52-4.

Innovative study that demonstrates the effectiveness of the association between Calcipotriol and Betamethasone in the treatment of other pathologies such as vitiligo, being able to reduce the classic discoloration that characterizes this pathology.

Method of use and dosage

TOKEN ®

Topical ointment with 50 mcg of Calcipotriol and 0.5 mg of Betamethasone per gram of product.

The definition of the therapeutic scheme is the responsibility of the competent doctor, who should take into account the patient's health and the severity of the clinical picture.

In general, however, the application of the correct amount of ointment directly on the skin regions affected by the pathological process, once a day for about 4 weeks for the scalp of 8 for the other regions, represents the most characteristic therapeutic procedure.

Warnings TOKEN ® Calcipotriol + Betamethasone

In order for the TOKEN ® therapy to be effective and safe, the patient, under a medical indication, should comply with certain health and hygiene regulations such as:

  • clean hands thoroughly after each application;
  • avoid application of the drug on injured skin regions;
  • avoid contact between eyes, mouth and mucous membranes and medication;
  • avoid exposure to solar radiation;
  • contact your doctor following the appearance of unwanted reactions;
  • keep the medicine out of the reach of children.

PREGNANCY AND BREASTFEEDING

The absence of clinical trials and studies able to characterize the safety profile of the pharmacotomy association Calcipotriol / Betamethasone for the health of the fetus and the suckling child, necessarily extends the aforementioned contraindications to the use of TOKEN ® also to pregnancy and the subsequent period breastfeeding.

Interactions

The patient receiving TOKEN ® should avoid the application of other products topically in the same treated skin area, especially those based on corticosteroids.

Contraindications TOKEN ® Calcipotriol + Betamethasone

The use of TOKEN ® is contraindicated in patients who are hypersensitive to the active ingredient or to one of its excipients, in patients with altered calcium metabolism, in the forms of guttate, erythrodermic, exfoliative and pustular psoriasis, in patients suffering from severe hepatic impairment and renal and in patients with skin infections, skin atrophy, capillary fragility, acne, ulcers, wounds and perianal itching.

Undesirable effects - Side effects

The therapy with TOKEN ® could determine the onset of local side effects, fortunately clinically not very relevant such as itching, redness, skin pain, erythema and burning.

The adverse reactions worthy of note are decidedly more rare.

Note

TOKEN ® is a prescription-only drug.

Interesting Articles